non squamous - mNSCLC - L1 - Wild Type (WT), atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. all, meta-analysis of study results
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;